Identification of Amino Acid Residues Important for Ligand Binding to Fas

The interaction of Fas (CD95), a member of the tumor necrosis factor receptor (TNFR) family, and its ligand (FasL) triggers programmed cell death (apoptosis) and is involved in the regulation of immune responses. Although the Fas–FasL interaction is conserved across species barriers, little is currently known about the molecular details of this interaction. Our aim was to identify residues in Fas that are important for ligand binding. With the aid of a Fas molecular model, candidate amino acid residues were selected in the Fas extracellular domain 2 (D2) and D3 and subjected to serine-scanning mutagenesis to produce mutant Fas molecules in the form of Ig fusion proteins. The effects of these mutations on FasL binding was examined by measuring the ability of these proteins to inhibit FasL-mediated apoptosis of Jurkat cells and bind FasL in ELISA and BIAcore™ assays. Mutation of two amino acids, R86 and R87 (D2), to serine totally abolished the ability of Fas to interact with its ligand, whereas mutants K84S, L90S, E93S (D2), or H126S (D3) showed reduced binding compared with wild-type Fas. Two mutants (K78S and H95S) bound FasL comparably to wild type. Therefore, the binding of FasL involves residues in two domains that correspond to positions critical for ligand binding in other family members (TNFR and CD40) but are conserved between murine and human Fas.

[1]  C. Smith,et al.  Identification of a source of biologically active CD40 ligand , 1992, European journal of immunology.

[2]  N. Jenkins,et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.

[3]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[4]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[5]  J Bajorath,et al.  Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. , 1995, Biochemistry.

[6]  D. Banner,et al.  Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.

[7]  J Bajorath,et al.  Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction. , 1995, Biochemistry.

[8]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[9]  S. Marsters,et al.  Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. , 1992, The Journal of biological chemistry.

[10]  G. Sutherland,et al.  Moslecular and biological characterization of human 4‐1BB and its ligands , 1994, European journal of immunology.

[11]  P. Kiener,et al.  Activation of human monocytes through CD40 induces matrix metalloproteinases. , 1996, Journal of immunology.

[12]  Jürgen Bajorath,et al.  Prediction of the three-dimensional structure of the human Fas receptor by comparative molecular modeling , 1997, J. Comput. Aided Mol. Des..

[13]  S. Nagata,et al.  Apoptosis: Telling cells their time is up , 1996, Current Biology.

[14]  J. Menonna,et al.  Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain , 1996, The Journal of experimental medicine.

[15]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[16]  P. Kiener,et al.  Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils , 1996, The Journal of experimental medicine.

[17]  A. Aruffo,et al.  Cleavable CD40Ig fusion proteins and the binding to sgp39. , 1995, Journal of immunological methods.

[18]  Stephen W. Fesik,et al.  NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain , 1996, Nature.

[19]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[20]  P. Galle,et al.  Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage , 1995, The Journal of experimental medicine.

[21]  K. Sullivan,et al.  Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. , 1996, The New England journal of medicine.

[22]  B. Modrell,et al.  The Membrane-proximal Scavenger Receptor Cysteine-rich Domain of CD6 Contains the Activated Leukocyte Cell Adhesion Molecule Binding Site (*) , 1995, The Journal of Biological Chemistry.

[23]  K. Yoshino,et al.  Metalloproteinase-mediated Release of Human Fas Ligand , 1995 .

[24]  I. Stamenkovic,et al.  The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co‐stimulatory activity. , 1992, The EMBO journal.